Stocks Health care LCTX
NYSE · Health careLineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. brought in $13.1M of revenue over the twelve months to June 30, 2026, up 19.9% from a year earlier. It posted a net loss of $32.3M. In fiscal 2025 capital spending exceeded operating cash flow by $19.4M. At June 30, 2026 it held $37.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Lineage Cell Therapeutics, Inc.
- Net worth
- Lineage Cell Therapeutics, Inc. has a market value (market cap) of $273.1M at the latest share price, and shareholders' equity of $60.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $14.6M (+53.2% year on year), with a net loss of $63.5M. Over the 12 months to June 30, 2026: revenue $13.1M, net loss $32.3M.
- Cash flow
- In fiscal 2025 operations used $18.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lineage Cell Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Lineage Cell Therapeutics, Inc. does
Lineage Cell Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker LCTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.6M | -$63.5M | -$0.28 | -$19.4M |
| 2024 | $9.5M | -$18.6M | -$0.09 | -$23.7M |
| 2023 | $8.9M | -$21.5M | -$0.12 | -$29.2M |
| 2022 | $14.7M | -$26.3M | -$0.15 | $646K |
| 2021 | $4.3M | -$43M | -$0.26 | -$23.9M |
| 2020 | $1.8M | -$20.6M | -$0.14 | -$19.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LCTX ranks in Health care
Latest SEC filings
What Lineage Cell Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 61% to $1.1M versus the same quarter last year; diluted EPS -$0.03 versus -$0.13.
- August 6, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 12, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 15% to $1.7M versus the same quarter last year; diluted EPS -$0.03 versus -$0.02.
- May 12, 2026
- April 29, 2026
- April 29, 2026Additional proxy material DEFA14A
- April 29, 2026Proxy statement DEF 14A
- March 11, 2026
Insider trades
What the people running Lineage Cell Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 12, 2026 | Culley Brian MPresident and CEO, Director | Bought | 15,000 | $24.4K |
| February 11, 2026 | Samuel George A. IIIGeneral Counsel and Secretary | Exercised options | 6,075 | - |
| February 11, 2026 | Samuel George A. IIIGeneral Counsel and Secretary | Shares withheld for tax | 2,502 | $4.5K |
| February 11, 2026 | Culley Brian MPresident and CEO, Director | Exercised options | 31,250 | - |
| February 11, 2026 | Culley Brian MPresident and CEO, Director | Shares withheld for tax | 12,869 | $23.2K |
| December 19, 2025 | Samuel George A. IIIGeneral Counsel and Secretary | Received as pay | 1,735 | - |
| December 19, 2025 | Samuel George A. IIIGeneral Counsel and Secretary | Shares withheld for tax | 65 | $109.2 |
| December 19, 2025 | Culley Brian MPresident and CEO, Director | Received as pay | 8,925 | - |
Who owns LCTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Neal C. Bradsher13D, may seek influence with 2 related filers | 23.1% | November 14, 2025 |
| Chernett Jorey13G, passive | 5% | September 26, 2025 |
Largest institutional holders
Insiders
2 insiders reported holding 286,579 shares in total, about $309.5K at the last price.
| Holder | Shares |
|---|---|
| Culley Brian MPresident and CEO, Director | 255,516 |
| Samuel George A. IIIGeneral Counsel and Secretary | 31,063 |
Questions about LCTX
What does Lineage Cell Therapeutics, Inc. do?
Lineage Cell Therapeutics, Inc. is a company in the Health care sector, listed on NYSE as LCTX. Its shares trade on NYSE under the ticker LCTX.
What is Lineage Cell Therapeutics, Inc.'s net worth?
Lineage Cell Therapeutics, Inc. has a market value (market cap) of $273.1M at the latest share price, and shareholders' equity of $60.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lineage Cell Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $32.3M on revenue of $13.1M.
How much revenue does Lineage Cell Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Lineage Cell Therapeutics, Inc. reported revenue of $13.1M. That is 19.9% more than a year earlier.
When did Lineage Cell Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026.
When is Lineage Cell Therapeutics, Inc.'s next earnings report?
Lineage Cell Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare LCTX with
Follow LCTX
Get an email when Lineage Cell Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lineage Cell Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.